echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Nebulized inhaled mRNA-encoded membrane-localized antibodies for SARS-CoV-2 infection protection in hamsters

    Nebulized inhaled mRNA-encoded membrane-localized antibodies for SARS-CoV-2 infection protection in hamsters

    • Last Update: 2023-01-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    To date, 270 million people worldwide have been infected with SARS-CoV-2, and as of January 2022, COVID-19 has killed more than 5 million
    people worldwide 。 Although there are already two mRNA-based vaccines, including an adenovirus vector vaccine and multiple monoclonal antibody (mAb) therapies, which have received emergency use authorization from the US Food and Drug Administration (FDA) or conditional marketing authorization from the European Medicines Agency in the European Union for prevention and treatment, shortcomings such as vaccine safety concerns, insufficient antigen inactivation, and the need to rely on professionals to use mAbs have led scientists to try to develop a convenient self-administered method to limit the spread of the virus
    。 One of the main disadvantages of
    using mAbs for passive immunization and treatment is due to the high cost of use due to factors such as the large dose required for mAb treatment (10-100 mg kg-1) and the need to administer it in hospitals.

    Neutralizing mAbs through mRNA expression has the following advantages: (1) Unlike DNA and DNA-based viral vectors, mRNA does not normally enter the nucleus, thus reducing the risk of fusion with the
    host genome.
    And mRNA degradation is relatively fast, and long-term effects can be minimized; (2) The dose of mRNA required for direct delivery of the mAb to the desired site (respiratory tract) is much smaller (0.
    1-1 mg kg-1)
    compared to intravenous or intramuscular injection.

    Advanced Science published the research article "Nebulized mRNA-Encoded Antibodies Protect Hamsters from SARS-CoV-2" by Professor Philip J.
    Santangelo of Emory University and Professor Eric R.
    Lafontaine and Professor Robert J.
    Hogan of the University of Georgia in October 2022 Infection", the article developed a novel nebulized mRNA code to neutralize the mAb and validated it in a hamster infection model, confirming that the mAb can be effectively used in the prevention and treatment of SARS-CoV-2
    .

    The authors first verified the distribution of mRNA-encoded mAbs on cells and cell membranes, and confirmed that mAbs can effectively neutralize viruses
    in vitro.
    Furthermore, the expression distribution, effective concentration and half-life of mAb in hamsters were further studied by nebulized inhalation, and it was found that the expression distribution was in line with expectations, and the half-life was significantly prolonged, and it was found that the mAb did not cause obvious damage
    to hamster lung tissue.
    In addition to the treatment of pre-existing infections, the authors also studied the mAb's preventive effect on SARS-CoV-2 and found that it was effective in preventing hamsters from infection and improving body weight, viral titers, viral load, and inflammation of lung tissue
    .
    Overall, this study provides a new strategy
    for the prevention and treatment of SARS-CoV-2 infection.

    The first author of the article is Daryll Vanover, and the corresponding authors are Philip J.
    Santangelo of Emory University and Eric R.
    Lafontaine and Robert
    J.
    Hogan of the University of Georgia.


    WILEY


    Paper Information:

    Nebulized mRNA-Encoded Antibodies Protect Hamsters from SARS-CoV-2 Infection.

    Vanover, D.
    , Zurla, C.
    , Peck, H.
    E.
    , Orr-Burks, N.
    , Joo, J.
    Y.
    , Murray, J.
    , Holladay, N.
    , Hobbs, R.
    A.
    , Jung, Y.
    , Chaves, L.
    C.
    S.
    , Rotolo, L.
    , Lifland, A.
    W.
    , Olivier, A.
    K.
    , Li, D.
    , Saunders, K.
    O.
    , Sempowski, G.
    D.
    , Crowe, J.
    E.
    , Haynes, B.
    F.
    , Lafontaine, E.
    R.
    , Hogan, R.
    J.
    , Santangelo, P.
    J.

    Nebulized mRNA-Encoded Antibodies Protect Hamsters from SARS-CoV-2 Infection.

    Adv.
    Sci.
     2022, 2202771.
     

    Click "Read Original" in the lower left corner to view the original text
    of the paper.





    AdvancedScienceNews

    Wiley's official WeChat platform for scientific research information

    Long press the QR code to follow us

    Share cutting-edge information | focus on scientific research trends

    To publish research news or apply for information sharing, please contact: ASNChina@Wiley.
    com


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.